AGTX (Agentix) ROC %: -76.90% (As of Dec. 2025)

What is Agentix ROC %?

Agentix AGTX -8.09% ROC % is -76.90% as of Dec. 2025. The stock has 3 warning signs investors should review.

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Agentix's annualized return on capital (ROC %) for the quarter that ended in Dec. 2025 was -76.90%.

As of today (2026-06-25), Agentix's WACC % is 26.55%. Agentix's ROC % is -189.74% (calculated using TTM income statement data). Agentix earns returns that do not match up to its cost of capital. It will destroy value as it grows.

Agentix (OTCPK:AGTX) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Agentix's WACC % is 26.55%. Agentix's ROC % is -189.74% (calculated using TTM income statement data). Agentix earns returns that do not match up to its cost of capital. It will destroy value as it grows.

Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Agentix ROC % Related Terms

Agentix ROC % Historical Data

* Premium members only.

The historical data trend for Agentix's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Agentix ROC % Chart

Agentix Annual Data

Trend

Aug15

Aug16

Aug17

Aug18

Aug19

Aug20

Aug21

Mar23

Mar24

Mar25

ROC %

Get a 7-Day Free Trial

0.00

-2,744.00

-772.02

-265.80

Agentix Quarterly Data
	Feb21	May21	Aug21	Nov21	Feb22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25
ROC %	Get a 7-Day Free Trial															-209.16	-312.02	-273.04	-143.23	-76.90

Agentix ROC % Calculation

Agentix's annualized Return on Capital (ROC %) for the fiscal year that ended in Mar. 2025 is calculated as:

	ROC % (A: Mar. 2025 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (A: Mar. 2024 )	+	Invested Capital (A: Mar. 2025 ))	/ count )
=	-0.513 * ( 1 - 0% )	/	( (0.143	+	0.243)	/ 2 )
=	-0.513	/	0.193
=	-265.80 %

where

	Invested Capital		(A: Mar. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0.106	-	2.524	-	( 0.007	-	max(0, 2.667	-	0.106	+	0.007	))
=	0.143

	Invested Capital		(A: Mar. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0.1	-	2.962	-	( 0.004	-	max(0, 3.205	-	0.1	+	0.004	))
=	0.243

Agentix's annualized Return on Capital (ROC %) for the quarter that ended in Dec. 2025 is calculated as:

	ROC % (Q: Dec. 2025 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Sep. 2025 )	+	Invested Capital (Q: Dec. 2025 ))	/ count )
=	-0.268 * ( 1 - 0% )	/	( (0.344	+	0.353)	/ 2 )
=	-0.268	/	0.3485
=	-76.90 %

where

	Invested Capital		(Q: Sep. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0.006	-	3.08	-	( 0.006	-	max(0, 3.424	-	0.006	+	0.006	))
=	0.344

	Invested Capital		(Q: Dec. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0.006	-	3.151	-	( 0.006	-	max(0, 3.504	-	0.006	+	0.006	))
=	0.353

Note: The Operating Income data used here is four times the quarterly (Dec. 2025) data. The tax rate is limited to between 0% and 100%.

Frequently Asked Questions Learn more about ROC % →

What does a ROC % of -76.90% mean?

Agentix (AGTX) has a ROC % of -76.90% as of Dec. 2025. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Agentix and its competitors.

Is Agentix's ROC % too high?

Agentix's current ROC % is -76.90%.

How does Agentix's ROC % compare to CERO and EVFM?

Agentix's ROC % of -76.90% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROC % for a Biotechnology company?

A good ROC % depends on the Biotechnology industry context. However, ROC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROC % mean?

A high ROC % can signal that a stock is expensive relative to its fundamentals. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Agentix and its competitors. Agentix's current ROC % is -76.90%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Agentix stock overvalued right now?

Agentix (AGTX) has a current ROC % of -76.90%. The current ROC % is -76.90%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROC % calculated?

ROC % is calculated from a company's financial statements. For Agentix (AGTX), the current ROC % is -76.90% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Agentix Business Description

Industry Healthcare Biotechnology

Comparable Companies CERO EVFM EMMA PTIX ATXI ABPO WINT RMTG LIPO CYTOF VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Address 32932 Pacific Coast Highway, No. 14-254, Dana Point, CA, USA, 92629

Website https://www.agentixcorp.com

Agentix Corp is a biotechnology company. Through its subsidiary, it is engaged in the development and commercialization of novel therapeutics to treat metabolic diseases, peripheral neuropathy, progressive lung disease, and ischemic reperfusion injury. Its principal business objective is to develop both science-driven synthetic and natural cannabinoid therapeutics that address unmet medical needs and continue to drive innovations in the endocannabinoid space. Its pipeline of drug candidates includes AGTX-2004, a CB1 receptor antagonist that has demonstrated efficacy in animal models of obesity and type 2 diabetes mellitus (T2DM), and AGTX-2003 a peripherally-acting CB1 receptor inverse agonist that has demonstrated efficacy in animal models of obesity and non-alcoholic fatty liver disease.